The Latest

  • A technician wearing a blue mask works in a laboratory.
    Image attribution tooltip
    Kevin Frayer via Getty Images
    Image attribution tooltip
    China competition

    Drugs from China are reshaping biotech. Track the licensing deals here.

    Hengrui’s $2.6 billion deal with Novo is its sixth with a major U.S. or European drugmaker since the start of 2025, the most of any China-based biopharmaceutical company over that timeframe.

    Updated Sept. 29, 2026
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    PhRMA names next CEO; Pierre Fabre takes third swing at Ebvallo approval

    A former congressman will take over for prominent lobbyist Steve Ubl. Elsewhere, recent buyout deals paid dividends for Mirum and AbbVie.

  • The exterior of the building housing the headquarters of Roche France, French subsidiary of the Swiss pharmaceutical group.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    FDA starts review of Roche’s multiple sclerosis pill

    The FDA previously hadn’t ever accepted an application of a drug like fenebrutinib in two major forms of MS. But safety questions still hang over Roche’s program.

  • dna helix
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Gene editing

    Beam sues 2 biotechs, alleging theft of base editing trade secrets

    Beam claimed a former scientist stole confidential information and quietly spun up a rival rare disease treatment at YolTech Therapeutics. Serapha Bio, which licensed that therapy, denies the charges. 

  • An illustration of DNA against a blue abstract background
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    UniQure tumbles with latest data for Huntington’s gene therapy

    Analysts guessed that investors wanted to see stronger durability results at a four-year check-in of the key trial supporting a potential approval of "AMT-130."

  • Close-up view of the Novo Nordisk logo mounted on the exterior wall of a building. The logo features a stylized blue Apis bull with a sun disk above its head, symbolizing the company's identity. The background shows a tan brick wall and part of a leafless tree in the foreground under a clear blue sky."
    Image attribution tooltip
    Alamy
    Image attribution tooltip
    Obesity drugs

    Novo to pay Hengrui up to $2.6B for a once-weekly obesity pill

    The deal, which hands Novo a challenger to Lilly’s market-leading Zepbound, comes as the Danish drugmaker looks to calm investor fears about its future.

  • A thumbnail illustration for BioPharma Dive's IPO tracker
    Image attribution tooltip
    Adeline Kon/BioPharma Dive
    Image attribution tooltip
    Deep Dive // IPO window

    Biotech IPOs are the industry’s lifeblood. Track how they’re performing.

    On the same day RNAi drugmaker ADARx priced one of 2026’s biggest biotech IPOs, City Therapeutics — a maker of next-generation RNAi medicines — joined the queue.

    Updated Sept. 25, 2026
  • An illustration of leukocytes attacking a cancer cell
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    AstraZeneca invests $2B in Summit, gaining ‘seat at the table’ for PD-1/VEGF drug push

    The equity investment comes alongside a deal to test Summit’s ivonescimab alongside potentially many AstraZeneca drugs — but doesn’t hand the pharmaceutical company any ownership rights.

  • An illustration of a macrophage releasing cytokines.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Immune reset

    ai3Bio, built from two biotechs, pursues a different path to an ‘immune reset’

    Rather than deplete malfunctioning B cells as many other emerging autoimmune drugs do, Ai3Bio’s therapies are designed to eliminate a particular group of T helper cells.

  • eye
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Kodiak skyrockets on positive study data for 2 eye drugs

    The Phase 3 findings suggested Kodiak might have multiple threats to Regeneron’s Eylea and added more than $3 billion to the company’s market value.

  • An illustration of engineered CAR-T cells attacking a cancer cell.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Immune reset

    An ‘off-the-shelf’ CAR-T therapy from Adicet shows promise against lupus

    Data from an early trial showed the company’s “gamma delta” cell therapy surpassed benchmarks set by personalized CAR-T treatments tested in lupus.

  • Merck sign
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Merck, Daiichi end plans to seek speedy approval of lung cancer ADC

    The FDA indicated that the data generated so far wouldn’t support an accelerated clearance of “I-DXd,” a setback that erases an edge Merck and Daiichi had over multiple fast-moving competitors.

  • A double exposure image of a glass flask in a laboratory with stock market information in the background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    This week in charts: Novo’s rise and fall and AI biotechs’ big haul

    The latest installment in BioPharma Dive’s data visualization series features a closer look at Novo's stock performance and the recent run of fundraising success for AI drug discovery startups.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Novo pursues long-acting obesity drugs; Acadia slumps on Alzheimer’s data

    Novo’s latest alliance involves injectables given every one to three months. Elsewhere, Nektar won a legal spat with Eli Lilly and the FDA issued two approvals.

  • Front view of the NASDAQ MarketSite, which occupies the northwest corner at the base of the 4 Times Square building, in Midtown Manhattan, New York City.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    IPO window

    RNAi drug specialist ADARx raises $446M IPO

    ADARx is the only maker of RNA-based drugs to go public since 2024 and the first RNAi biotech to price an IPO in the U.S. in more than a decade.

  • An all-green glass building facade with a logo that reads "MERCK" is displayed on the exterior of the research facility.
    Image attribution tooltip
    Alamy
    Image attribution tooltip

    Merck reveals study success, and possible safety worries, for eye drug hopeful

    A medicine acquired in a $1.3 billion buyout came through in the first of two pivotal studies in diabetic macular edema, though language regarding the drug’s safety stirred debate among analysts.

  • FDA Commissioner nominee Heidi Overton testifies before Senate committee.
    Image attribution tooltip
    Tasos Katopodis via Getty Images
    Image attribution tooltip
    Trump administration

    FDA nominee Overton parries vaccine questions at Senate hearing

    Pressed by lawmakers on Thursday, Trump’s pick as the next FDA chief said she’d “follow the law” on key decisions and work to speed early drug research.

    FDA
  • EU Visa Mastercard card networks Europe
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    China competition

    9 pharma leaders sound ‘alarm bells’ on biotech’s decline in Europe

    Frustrated by a slump that’s seen Europe lose ground to the U.S. and China, several top drugmakers are calling for speedier clinical trials, intellectual property protections and “fiscal flexibility.”

  • A hand in a blue glove holds a blood sample.
    Image attribution tooltip
    Courtesy of Grail
    Image attribution tooltip

    Grail multicancer detection test wins FDA advisers’ backing

    Panel members said the first-of-a-kind blood test should not be used to replace medical guideline-recommended cancer screenings, however.

    FDA
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Lilly’s latest China drug deal; Immunovant’s setback in lupus

    Lilly wagered up to $3.35 billion in its fourth China-focused alliance since January 2025. Elsewhere, analysts are now more confident about one of Vertex’s top prospects and an RNA drug succeeded against a rare form of ALS.

  • A laboratory scientist works with plants. Their hands are visible through several potted plants and their leaves.
    Image attribution tooltip
    Permission granted by Enveda Biosciences
    Image attribution tooltip
    Emerging biotech

    Enveda, an AI drugmaker, banks $311M in venture funding

    Enveda, which is using AI tools to mine plants and microbes for drug prospects, has three candidates in human testing for immune diseases and obesity.

  • An illustration of the kidneys, colored red and blue.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Roche, Ionis RNA drug scores in kidney disease study

    The results position Roche to bring a new kind of medicine to market for IgA nephropathy, a disease that’s drawn considerable attention of late from drugmakers. 

  • President Donald Trump holds up a chart comparing drug prices and Medicare Part D costs during a healthcare affordability event in the Oval Office.
    Image attribution tooltip
    Kevin Dietsch via Getty Images
    Image attribution tooltip
    Trump administration

    A hidden tradeoff in Trump’s drug pricing deals

    The government has announced “most-favored-nation” pricing agreements with 26 pharma companies. But the deals could stymie other plans to lower the country’s spending on prescription drugs.

  • Shrugs and trees surround a large metal Amgen sign displayed outside a modern office building.
    Image attribution tooltip
    Alamy
    Image attribution tooltip

    Amgen reports a Phase 3 win with Sjögren’s drug candidate

    Dazodalibep, acquired in Amgen’s big buyout of Horizon Therapeutics, succeeded in the first of two late-stage trials against the tough-to-treat autoimmune disorder.

  • A picture of tablets and injectable medicines for obesity.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Obesity drugs

    Viking shares surge on updated obesity drug data

    Trial participants mostly kept their weight down after switching from a weekly shot to less frequent dosing — findings that could strengthen Viking’s “competitive positioning,” one analyst wrote.